Molecular subtypes and imaging phenotypes of breast cancer

Ultrasonography

Volumn 35, Issue 4, 2016, Pages 281-288

  Cho, Nariya ^a,b  

^a Seoul National University Hospital   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

Author keywords

Breast neoplasms; Diagnosis; Gene expression profiling; Ultrasonography

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2;

BREAST CANCER; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL (TOPIC); DISEASE FREE SURVIVAL; GENE EXPRESSION PROFILING; HUMAN; IN SITU HYBRIDIZATION; LUMINAL A BREAST CANCER; LUMINAL B BREAST CANCER; MOLECULAR DIAGNOSIS; PERSONALIZED MEDICINE; PHENOTYPE; POLYMERASE CHAIN REACTION; RECURRENCE FREE SURVIVAL; REVIEW; TREATMENT RESPONSE; TUMOR VOLUME;

EID: 85013425415     PISSN: 22885919     EISSN: 22885943     Source Type: Journal    
DOI: 10.14366/usg.16030     Document Type: Review

References (39)

1. Ng CK, Schultheis AM, Bidard FC, Weigelt B, Reis-Filho JS. Breast cancer genomics from microarrays to massively parallel sequencing:paradigms and new insights. J Natl Cancer Inst 2015; 107:djv015.
2. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 2012; 490: 61-70.
3. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001; 98: 10869-10874.
4. Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 2009; 27: 1160-1167.
5. Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thurlimann B, et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol 2013; 24: 2206-2223.
6. Coates AS, Winer EP, Goldhirsch A, Gelber RD, Gnant M, Piccart-Gebhart M, et al. Tailoring therapies: Improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Ann Oncol 2015; 26: 1533-1546.
7. Polyak K. Breast cancer: origins and evolution. J Clin Invest 2007; 117: 3155-3163.
8. Prat A, Pineda E, Adamo B, Galvan P, Fernandez A, Gaba L, et al. Clinical implications of the intrinsic molecular subtypes of breast cancer. Breast 2015; 24 Suppl 2:S26-S35.
9. Prat A, Adamo B, Cheang MC, Anders CK, Carey LA, Perou CM. Molecular characterization of basal-like and non-basal-like triplenegative breast cancer. Oncologist 2013; 18: 123-133.
10. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 2011; 121: 2750-2767.
11. Liedtke C, Mazouni C, Hess KR, Andre F, Tordai A, Mejia JA, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 2008; 26: 1275-1281.
12. Chia SK, Bramwell VH, Tu D, Shepherd LE, Jiang S, Vickery T, et al. A 50-gene intrinsic subtype classifier for prognosis and prediction of benefit from adjuvant tamoxifen. Clin Cancer Res 2012; 18: 4465-4472.
13. Prat A, Parker JS, Fan C, Cheang MC, Miller LD, Bergh J, et al. Concordance among gene expression-based predictors for ERpositive breast cancer treated with adjuvant tamoxifen. Ann Oncol 2012; 23: 2866-2873.
14. Iwamoto T, Booser D, Valero V, Murray JL, Koenig K, Esteva FJ, et al. Estrogen receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1% to 10% ER-positive by immunohistochemistry. J Clin Oncol 2012; 30: 729-734.
15. Reis-Filho JS, Pusztai L. Gene expression profiling in breast cancer: Classification, prognostication, and prediction. Lancet 2011; 378: 1812-1823.
16. Arteaga CL, Sliwkowski MX, Osborne CK, Perez EA, Puglisi F, Gianni L. Treatment of HER2-positive breast cancer: Current status and future perspectives. Nat Rev Clin Oncol 2012; 9: 16-32.
17. Perez EA, Romond EH, Suman VJ, Jeong JH, Davidson NE, Geyer CE Jr, et al. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol 2011; 29: 3366-3373.
18. Vaz-Luis I, Ottesen RA, Hughes ME, Marcom PK, Moy B, Rugo HS, et al. Impact of hormone receptor status on patterns of recurrence and clinical outcomes among patients with human epidermal growth factor-2-positive breast cancer in the National Comprehensive Cancer Network: A prospective cohort study. Breast Cancer Res 2012; 14:R129.
19. Gianni L, Eiermann W, Semiglazov V, Lluch A, Tjulandin S, Zambetti M, et al. Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): Follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet Oncol 2014; 15: 640-647.
20. Dogan BE, Turnbull LW. Imaging of triple-negative breast cancer. Ann Oncol 2012; 23 Suppl 6:vi23-vi29.
21. Chang JM, Park IA, Lee SH, Kim WH, Bae MS, Koo HR, et al. Stiffness of tumours measured by shear-wave elastography correlated with subtypes of breast cancer. Eur Radiol 2013; 23: 2450-2458.
22. Youk JH, Gweon HM, Son EJ, Kim JA, Jeong J. Shear-wave elastography of invasive breast cancer: Correlation between quantitative mean elasticity value and immunohistochemical profile. Breast Cancer Res Treat 2013; 138: 119-126.
23. Ganau S, Andreu FJ, Escribano F, Martin A, Tortajada L, Villajos M, et al. Shear-wave elastography and immunohistochemical profiles in invasive breast cancer: evaluation of maximum and mean elasticity values. Eur J Radiol 2015; 84: 617-622.
24. Luck AA, Evans AJ, James JJ, Rakha EA, Paish EC, Green AR, et al. Breast carcinoma with basal phenotype: Mammographic findings. AJR Am J Roentgenol 2008; 191: 346-351.
25. Uematsu T, Kasami M, Yuen S. Triple-negative breast cancer:correlation between MR imaging and pathologic findings. Radiology 2009; 250: 638-647.
26. Youk JH, Son EJ, Chung J, Kim JA, Kim EK. Triple-negative invasive breast cancer on dynamic contrast-enhanced and diffusionweighted MR imaging: Comparison with other breast cancer subtypes. Eur Radiol 2012; 22: 1724-1734.
27. Irshad A, Leddy R, Pisano E, Baker N, Lewis M, Ackerman S, et al. Assessing the role of ultrasound in predicting the biological behavior of breast cancer. AJR Am J Roentgenol 2013; 200: 284-290.
28. Aho M, Irshad A, Ackerman SJ, Lewis M, Leddy R, Pope TL, et al. Correlation of sonographic features of invasive ductal mammary carcinoma with age, tumor grade, and hormone-receptor status. J Clin Ultrasound 2013; 41: 10-17.
29. Shin HJ, Kim HH, Huh MO, Kim MJ, Yi A, Kim H, et al. Correlation between mammographic and sonographic findings and prognostic factors in patients with node-negative invasive breast cancer. Br J Radiol 2011; 84: 19-30.
30. Mazurowski MA, Zhang J, Grimm LJ, Yoon SC, Silber JI. Radiogenomic analysis of breast cancer: luminal B molecular subtype is associated with enhancement dynamics at MR imaging. Radiology 2014; 273: 365-372.
31. Kawashima H, Inokuchi M, Furukawa H, Kitamura S. Triplenegative breast cancer: Are the imaging findings different between responders and nonresponders to neoadjuvant chemotherapy? Acad Radiol 2011; 18: 963-969.
32. Bae MS, Shin SU, Ryu HS, Han W, Im SA, Park IA, et al. Pretreatment MR imaging features of triple-negative breast cancer: Association with response to neoadjuvant chemotherapy and recurrence-free survival. Radiology 2016 May 19 [Epub]. http://dx.doi.org/10.1148/ radiol.2016152331.
33. Elias SG, Adams A, Wisner DJ, Esserman LJ, van’t Veer LJ, Mali WP, et al. Imaging features of HER2 overexpression in breast cancer: A systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev 2014; 23: 1464-1483.
34. Grimm LJ, Johnson KS, Marcom PK, Baker JA, Soo MS. Can breast cancer molecular subtype help to select patients for preoperative MR imaging? Radiology 2015; 274: 352-358.
35. Li H, Zhu Y, Burnside ES, Drukker K, Hoadley KA, Fan C, et al. MR imaging radiomics signatures for predicting the risk of breast cancer recurrence as given by research versions of MammaPrint, Oncotype DX, and PAM50 gene assays. Radiology 2016 May 5 [Epub]. http://dx.doi.org/10.1148/radiol.2016152110.
36. Dialani V, Gaur S, Mehta TS, Venkataraman S, Fein-Zachary V, Phillips J, et al. Prediction of low versus high recurrence scores in estrogen receptor-positive, lymph node-negative invasive breast cancer on the basis of radiologic-pathologic features: Comparison with Oncotype DX test recurrence scores. Radiology 2016; 280: 370-378.
37. Sutton EJ, Oh JH, Dashevsky BZ, Veeraraghavan H, Apte AP, Thakur SB, et al. Breast cancer subtype intertumor heterogeneity: MRIbased features predict results of a genomic assay. J Magn Reson Imaging 2015; 42: 1398-1406.
38. Yepes MM, Romilly AP, Collado-Mesa F, Net JM, Kiszonas R, Arheart KL, et al. Can mammographic and sonographic imaging features predict the Oncotype DX recurrence score in T1 and T2, hormone receptor positive, HER2 negative and axillary lymph node negative breast cancers? Breast Cancer Res Treat 2014; 148: 117-123.
39. Thrall JH. Moreton lecture: Imaging in the age of precision medicine. J Am Coll Radiol 2015; 12: 1106-1111.